Abstract
It was recently suggested that prostaglandin release (especially PGE1 and PGF(2α)) plays a key role in the development of the migrainous attack. Based on this hypothesis a therapeutic trial with flufenamic acid (a prostaglandin inhibitor of the fenamates group) was conducted during 1 yr in 5 patients suffering from recurrent ophthalmoplegic migraine. We treated 25 migrainous attacks; in 22 of them the patients reported marked alleviation of the headaches and only in 2 occasions a partial third nerve palsy accompanied the attack.
| Original language | English |
|---|---|
| Pages (from-to) | 148-152 |
| Number of pages | 5 |
| Journal | Ophthalmologica |
| Volume | 175 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1977 |
| Externally published | Yes |